Icosavax Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Icosavax Inc (ICVX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Icosavax Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 1M vs 123,105M combined for tracked competitors (0.0% combined share).
- Peer differentiation: Revenue per employee of $0.02M compares with $1.65M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Icosavax Inc vs. its Competitors, Q3 2023
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Icosavax Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Icosavax Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Icosavax Inc's competitor groups requires a Commercial License.
Icosavax Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Icosavax Inc | - | - | - | Yes |
| Competitors combined (31) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ICVX Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Immunitybio inc | 282.9% | Outperformed |
| 3 | Tourmaline Bio Inc | 282.9% | Outperformed |
| 4 | Vaxcyte Inc | 282.9% | Outperformed |
| 5 | Sutro Biopharma Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Icosavax Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Icosavax Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Icosavax Inc | 765.97 | 0.58 |
| Pfizer Inc | 163,675.28 | 63,696.00 |
| Gsk Plc | 102,307.45 | 32,667.00 |
| Sanofi | 100,940.42 | 52,321.04 |
| Moderna Inc | 78,517.44 | 2,228.00 |
| Biontech Se | 23,437.65 | 3,214.29 |
| SUBTOTAL | 507,056.58 | 155,772.47 |
Sign in to see all competitors of Icosavax Inc .
Sources: Icosavax Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Icosavax Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Icosavax Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Icosavax Inc | 766 | 18,774 | -3,119,742 |
| Pfizer Inc | 163,675 | 849,280 | 58,267 |
| Gsk Plc | 102,307 | 128,610,236 | 24,759,843 |
| Sanofi | 100,940 | 22,927,713 | 3,853,252 |
| Moderna Inc | 78,517 | 474,043 | -670,426 |
| Biontech Se | 23,438 | 411,719 | -162,986 |
| PEERS TOTAL | 506,291 | 1,652,068 | 118,984 |
Icosavax Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Pfizer Inc | United States 58.91 % |
| Immunitybio inc | United States 98.99 % |
| Novavax inc | United States 68.88 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Icosavax Inc's Business Segment Mix vs Peers
Revenue by operating segment, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Pfizer Inc | U.S. Commercial Division 52.92 % |
| Immunitybio inc | Reportable 100.00 % |
| Novavax inc | Reportable 100.00 % |
| Armata Pharmaceuticals Inc | Single Reportable Segment 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Icosavax Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (93 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.7x | - |
| EV / EBITDA | - | 21.3x | - |
| P/B | 1.7x | 5.1x | -3.4x |
| Return on Equity | -43.06 % | industry aggregate | -49.18 % |
| Return on Invested Capital | -23.24 % | -6.17 % (avg) | -17.07 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Icosavax Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) — not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 49.2 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- Industry revenue growing at a healthy 10.0% median pace.
- A meaningful share of tracked competitors (44.80 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-49.4% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Icosavax Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Icosavax Inc | 5.97 | 16.68 | - |
| Pfizer Inc | 0.04 | 1.24 | 0.71 |
| Gsk Plc | - | - | - |
| Sanofi | 0.27 | 1.09 | 0.20 |
| Moderna Inc | 0.86 | 2.88 | 0.07 |
| Biontech Se | 3.58 | 7.54 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Icosavax Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Icosavax Inc | Q3 2023 | - | - |
| Pfizer Inc | Q2 2026 | +2.6 % | - |
| Gsk Plc | Q4 2025 | +4.1 % | +113.1 % |
| Sanofi | Q4 2025 | +5.5 % | +39.7 % |
| Moderna Inc | Q2 2026 | +2.1 % | - |
| Biontech Se | Q4 2025 | +4.3 % | - |
| PEERS TOTAL | +4.9 % | +22.0 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Icosavax Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Icosavax Inc | Q3 2023 | - | -99.2 % |
| Pfizer Inc | Q2 2026 | +8.3 % | -13.8 % |
| Gsk Plc | Q4 2025 | +2.9 % | -0.6 % |
| Sanofi | Q4 2025 | -1.2 % | - |
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
| Biontech Se | Q4 2025 | +18.6 % | -38.9 % |
Icosavax Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Icosavax Inc | - | - | - |
| Pfizer Inc | 2.12% | 2.53% | 4.91% |
| Gsk Plc | 10.29% | 51.22% | 39.41% |
| Sanofi | 6.19% | 8.42% | 10.95% |
| Moderna Inc | - | - | - |
| Biontech Se | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Icosavax Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Icosavax Inc | - | 1,316.10 |
| Pfizer Inc | 37.66 | 2.57 |
| Gsk Plc | 17.90 | 3.13 |
| Sanofi | 11.43 | 1.93 |
| Moderna Inc | - | 35.24 |
| Biontech Se | - | 7.29 |
| PEERS AVERAGE | 45.59 | 3.26 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.